Overview

• Health and wellness firm's Q4 revenue fell 36.9% yr/yr due to fewer active coaches

• Company reported Q4 net loss of $18.1 mln, impacted by tax provision charge

• Medifast reinstates annual guidance, focusing on metabolic health strategy

Outlook

• Medifast expects Q1 2026 revenue between $65 mln and $80 mln

• Medifast forecasts full-year 2026 revenue between $270 mln and $300 mln

• Company anticipates Q1 2026 loss per share between $0.15 and $0.70

Result Drivers

• FEWER ACTIVE COACHES - Revenue decline primarily driven by a 40.6% decrease in active earning coaches, reflecting challenges in client acquisition and competition from GLP-1 medications

• INCREASED COACH PRODUCTIVITY - Revenue per active earning coach rose 6.2% year-over-year, attributed to better alignment and prioritization of productive coaches

• GROSS MARGIN DECLINE - Gross profit margin fell due to loss of leverage on fixed costs and a one-time restructuring charge

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the food processing peer group is "buy."

• Wall Street's median 12-month price target for Medifast Inc is $15.00, about 39.3% above its February 13 closing price of $10.77

Press Release: ID:nBw4qQTLVa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)